Compare NEXA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | COLL |
|---|---|---|
| Founded | 1956 | 2002 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.2B |
| IPO Year | 2017 | 2015 |
| Metric | NEXA | COLL |
|---|---|---|
| Price | $9.63 | $34.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $8.13 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 700.2K | 514.3K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $6.99 | $5.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.47 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $4.62 | $23.23 |
| 52 Week High | $14.94 | $50.79 |
| Indicator | NEXA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 28.83 |
| Support Level | $4.86 | $34.29 |
| Resistance Level | $14.84 | $36.20 |
| Average True Range (ATR) | 0.72 | 1.36 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 16.93 | 5.72 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.